Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Arcturus Therapeutics is a clinical-stage mRNA therapeutics company focused on rare diseases and infectious disease vaccines, leveraging its proprietary LUNAR lipid nanoparticle delivery platform and self-amplifying RNA (sa-RNA) technology. The company's lead programs include ARCT-810 for ornithine transcarbamylase (OTC) deficiency and ARCT-032 for cystic fibrosis, with operations spanning US and Asian markets through partnerships including CSL Seqirus and Ultragenyx. The stock trades at 0.9x book value with significant cash burn ($100M+ annually) and minimal revenue, making it a high-risk, binary-outcome biotechnology investment dependent on clinical trial readouts and regulatory approvals.
Arcturus operates a platform-based model monetizing its LUNAR lipid nanoparticle delivery technology and self-amplifying RNA through: (1) upfront licensing fees and milestone payments from pharmaceutical partners who gain access to its delivery platform, (2) royalties on future commercial sales of partnered products, and (3) potential wholly-owned product revenues if clinical programs reach commercialization. The company's competitive advantage lies in its sa-RNA technology requiring lower doses (potentially 1/10th of conventional mRNA) which could reduce manufacturing costs and improve safety profiles. With 100% gross margins on collaboration revenue but negative operating margins of -69%, the business model depends entirely on advancing clinical assets to value-inflection points (Phase 2/3 data, regulatory approvals) that trigger milestone payments or acquisition interest.
Clinical trial data readouts for ARCT-810 (OTC deficiency Phase 2/3) and ARCT-032 (cystic fibrosis) - binary events that can move stock 30-50%+
Regulatory interactions and FDA guidance on development pathways for rare disease programs, particularly accelerated approval eligibility
Partnership announcements, milestone achievements, or expansion of collaboration terms with CSL Seqirus, Ultragenyx, or new partners
Cash runway updates and financing activities (equity raises, debt facilities) given $100M+ annual burn rate
Competitive developments in mRNA delivery technology and rare disease treatment landscape (Moderna, BioNTech, Translate Bio acquisitions)
Clinical trial failure risk - Phase 2/3 programs have 30-40% historical success rates in rare diseases, with binary outcomes that could render platform value negligible
mRNA delivery technology commoditization as Moderna, BioNTech, and other well-capitalized competitors advance lipid nanoparticle platforms with superior resources
Regulatory pathway uncertainty for rare disease accelerated approvals, particularly as FDA scrutiny on surrogate endpoints intensifies post-2023
Reimbursement challenges for ultra-rare disease treatments requiring $500K-$2M+ annual pricing to achieve commercial viability
Moderna and BioNTech expanding into rare disease mRNA therapeutics with significantly larger cash reserves ($10B+ vs $150M) and established manufacturing infrastructure
Gene therapy competitors (BioMarin, Ultragenyx's own programs) offering potential one-time curative treatments versus chronic mRNA dosing for conditions like OTC deficiency
Acquisition of Translate Bio by Sanofi and Arbutus by Roivant consolidating mRNA delivery IP and creating well-funded competitive threats
Cash runway of 12-18 months (estimated) requires near-term financing, likely dilutive equity raise given current 0.9x P/B valuation and limited debt capacity
Negative operating cash flow of $100M annually with declining revenue (-12% YoY) creates urgency for clinical milestones or partnership expansions
Current ratio of 7.86x appears strong but absolute cash balance (~$150M estimated) insufficient for multiple Phase 3 trials without additional capital
Equity financing risk at depressed valuations (stock down 58% over 6 months) could result in 30-50%+ dilution in next raise
low - Pre-revenue biotech with clinical trial timelines largely independent of GDP growth or consumer spending. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines, (2) partner pharmaceutical companies' willingness to fund collaborations, and (3) government funding for vaccine programs. Rare disease focus provides some insulation as these are non-discretionary medical needs.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-10+ years for most biotech DCF models). Clinical-stage biotechs with no earnings trade primarily on NPV of pipeline assets, making them highly sensitive to risk-free rate changes. Additionally, higher rates increase opportunity cost of holding cash-burning equities versus bonds. With minimal debt (0.10 D/E), financing cost impact is negligible, but equity financing becomes more dilutive as cost of capital rises.
Minimal direct credit exposure as company has limited debt and operates on equity capital. However, credit market conditions indirectly affect: (1) ability to access convertible debt markets for non-dilutive financing, (2) venture debt availability for runway extension, and (3) broader biotech M&A activity as acquirers' financing costs rise. Widening high-yield spreads typically correlate with reduced risk appetite for speculative biotech equities.
growth/speculative - Attracts high-risk-tolerance biotech specialists, hedge funds with event-driven strategies around clinical catalysts, and retail investors seeking binary upside from rare disease approvals. Not suitable for value or income investors given negative earnings, no dividends, and 0.9x P/B reflecting distressed valuation. Institutional ownership likely concentrated among specialized healthcare funds rather than generalist long-only managers.
high - Clinical-stage biotech with binary trial readouts, small market cap ($200M), and limited liquidity creates extreme volatility. Stock down 58% over 6 months but up 13% over 3 months demonstrates event-driven price action. Implied volatility likely 80-100%+ with beta above 2.0x relative to broader market. Single clinical trial results can move stock 40-60% in either direction.
